NCT06851819View on ClinicalTrials.gov

Tislelizumab in Combination with Chemotherapy ± Radiotherapy for Extensive-Stage Oligometastatic Small Cell Lung Cancer.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

June 30, 2029

Conditions
Small Cell Lung Cancer Extensive Stage
Interventions
RADIATION

radiotherapy

Palliative radiotherapy for oligometastases can be combined with chemoradiotherapy and immunomaintenance therapy period. The investigator determines the number, timing and regimen of oligometastases according to the location, size, symptoms and patient tolerance of oligometastases

DRUG

immunechemotherapy

Tislelizumab in Combination With Chemotherapy(etoposide/cisplatin )

Trial Locations (1)

050000

Hebei Medical University Fourth Hospital, Shijiazhuang

All Listed Sponsors
lead

Hebei Medical University Fourth Hospital

OTHER